At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7508, a Monoclonal Antibody Against Factor XI, in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating REGN7508 (IV), REGN7508 (SC), and 2 other interventions for Healthy Volunteer. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This study is researching an experimental drug called REGN7508 (called "study drug"). The aim of this study is to see how safe and tolerable the study drug is in healthy participants. This study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Study Details
Timeline
Interventions
Administered sequential, ascending single intravenous (IV) dose
Administered sequential, ascending single subcutaneous (SC) dose
Administered sequential, ascending single intravenous (IV) dose
Administered sequential, ascending single subcutaneous (SC) dose